SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000950170-23-021783
Filing Date
2023-05-12
Accepted
2023-05-12 16:16:13
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A ikt-proxy-2023_defa14a.htm DEFA14A 19238
2 GRAPHIC img145634300_0.jpg GRAPHIC 1841366
3 GRAPHIC img145634300_1.jpg GRAPHIC 1470548
  Complete submission text file 0000950170-23-021783.txt   4581134
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-39676 | Film No.: 23915949
SIC: 2836 Biological Products, (No Diagnostic Substances)